- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02958839
Relationship Between Fibroblast Growth Factor 23 and Recurrence of Atrial Fibrillation After Catheter Ablation (REBECCA)
The Relationship Between Fibroblast Growth Factor 23 and the Recurrence of Atrial Fibrillation After Catheter Ablation: a Nested Case-Control Study
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Atrial fibrillation, which can result in stroke and thromboembolism in an approximately 5-fold increased risk, has been a great burden to health care system with the aging of population. Catheter ablation is the most promising treatment of atrial fibrillation. However, the recurrence rates of AF after catheter ablation are high, ranging from 20%-60%. Therefore, non-invasive predictors for AF recurrence after catheter ablation is necessary to select the optimal patients for this procedure.
Fibroblast growth factor-23 (FGF-23) is a bone-derived hormone that plays a central role in phosphate homeostasis. Recent study showed that fibroblast growth factor 23 plays an important role in cardiac remodeling and is considered to be independently associated with the occurrence of atrial fibrillation. In this study, we are going to observe the relationship between the serum FGF-23 and the arrythmia recurrence after catheter ablation of AF.
This research is going to recruit 200 consecutive patients with a history of atrial fibrillation for 180-360 days who intend to undergo catheter ablation. The day before catheter ablation, serum FGF-23 level will be detected. Echocardiogram and left atrial CT scan will also be performed on the day before catheter ablation. All patients will be routinely follow up in the outpatient department by cardiologists every month for 1 year. If patients complain about palpitations, fatigue, or other symptoms related to arrhythmia, Holter monitoring will be performed. Patients will also be advised to see their doctor anytime they have these symptoms and to undergo a 12-lead ECG examination or 24-hour Holter monitoring. In asymptomatic patients, 24-hour Holter monitoring or 7-day cardiac event recording will be performed every three months after the procedure. The endpoint for follow-up is the recurrence of atrial fibrillation, which is considered to be any episode of AF/AFL/AT after a blank period of 3 months after the procedure of catheter ablation. Those who develop recurrence of AF during follow up will be assigned to recurrence group, and those who do not develop recurrence of AF during follow up will be assigned to non-recurrence group. Comparison of the serum FGF-23 level between the two groups will be carried out in order to investigate the relationship between serum FGF-23 level and the recurrence of AF.
Tipo de estudio
Inscripción (Anticipado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Beijing
-
Beijing, Beijing, Porcelana, 100019
- Peking University Third Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Have a history of atrial fibrillation for 180 to 360 days
- Provide written informed consent, having understood the benefits and risks of participation in the trial
Exclusion Criteria:
- Significant structural heart disease (including symptomatic coronary heart disease; prosthetic mitral or tricuspid valve; congenital heart disease where abnormality or its correction prohibits or increases the risk of ablation)
- Atrial Fibrillation precipitated by other diseases (such as thyrotoxicosis)
- Severe dysfunction of liver or kidney
- Diabetes
- Malignant tumor
- Inability or refusal to provide written informed consent for the study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Control de caso
- Perspectivas temporales: Futuro
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
---|---|
Recurrence Group
In the case control trial, patients who have any episode of atrial fibrillation/atrial flutter/atrial tachycardia after a blanking period of 3 months from the catheter ablation procedure will be assign to the recurrence group
|
Patients with persistent or paroxysmal atrial fibrillation will go through catheter ablation
|
Non-recurrence Group
In the case control trial, patients who do not have any episode of atrial fibrillation/atrial flutter/atrial tachycardia after a blanking period of 3 months from the catheter ablation procedure will be assign to the recurrence group
|
Patients with persistent or paroxysmal atrial fibrillation will go through catheter ablation
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Incidence of the recurrence of atrial fibrillation
Periodo de tiempo: after 3 months from the procedure of catheter ablation
|
The recurrence of atrial fibrillation is considered to be any episode of AF/AFL/AT after a blank period of 3 months after the procedure of catheter ablation
|
after 3 months from the procedure of catheter ablation
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Plasma fibroblast growth factor 23 levels
Periodo de tiempo: after 3 months from the procedure of catheter ablation
|
Fibroblast Growth Factor 23 plays an important role in cardiac remodeling and is considered to be independently associated with the occurrence of atrial fibrillation
|
after 3 months from the procedure of catheter ablation
|
CHA2DS2-VASc score
Periodo de tiempo: after 3 months from the procedure of catheter ablation
|
CHA2DS2-VASc score is used to measure the risk of thrombotic event in patient with atrial fibrillation
|
after 3 months from the procedure of catheter ablation
|
Cardiac CT evaluation
Periodo de tiempo: after 3 months from the procedure of catheter ablation
|
To evaluate the degree of fibrosis of the left and right atrium and pulmonary veins
|
after 3 months from the procedure of catheter ablation
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Lei Li, MD, Peking University Third Hospital
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- L03-ZZK-FGF23
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Fibrilación auricular
-
The Second Affiliated Hospital of Chongqing Medical...TerminadoFibrilación auricular | Hipertensión,Esencial | Dilatación atrial izquierdaPorcelana
-
Region SkaneReclutamientoFibrilación auricular | Dilatación atrial izquierdaSuecia
-
Wake Forest University Health SciencesNational Heart, Lung, and Blood Institute (NHLBI)ReclutamientoEnfermedades Renales | Hipertensión | Obesidad Pediátrica | Proteinuria | Albuminuria | Lesión renal | Trastornos de la presión arterial | Disfunción autonómica | Enfermedad renal pediátrica | Disfunción Ventricular Izquierda | Hipertrofia del ventrículo izquierdo | Disfunción renal | Desequilibrio autonómico | Disfunción... y otras condicionesEstados Unidos
Ensayos clínicos sobre Catheter ablation
-
Abbott Medical DevicesReclutamientoTaquicardia auricular | Arritmia auricular | Atrio; FibrilaciónEstados Unidos
-
University Hospital MuensterTerminadoCarrera | DisfagiaAlemania
-
CSA Medical, Inc.TerminadoEnfermedades Pulmonares Obstructivas | Granulomatosis de Wegener | Sarcoidosis | Papilomatosis Respiratoria Recurrente | RinoescleromaEstados Unidos
-
Pier LambiaseUniversity Hospital Southampton NHS Foundation Trust; The Royal Bournemouth HospitalTerminadoFibrilación auricularReino Unido
-
Pamela Youde Nethersole Eastern HospitalTerminadoDiabetes mellitus | Hipertensión, Resistente | Terapia de denervación renalHong Kong
-
Charles University, Czech RepublicUniversity Hospital Olomouc; General University Hospital, Prague; Cardiocenter...TerminadoHipertensión | Resistente a la Terapia ConvencionalChequia
-
CSA Medical, Inc.TerminadoCáncer de pulmón | MesoteliomaEstados Unidos
-
Newmarket Electrophysiology Research Group IncMedtronicTerminado